Quantitative impact of pre‐analytical process on plasma uracil when testing for dihydropyrimidine dehydrogenase deficiency. Issue 2 (3rd October 2022)
- Record Type:
- Journal Article
- Title:
- Quantitative impact of pre‐analytical process on plasma uracil when testing for dihydropyrimidine dehydrogenase deficiency. Issue 2 (3rd October 2022)
- Main Title:
- Quantitative impact of pre‐analytical process on plasma uracil when testing for dihydropyrimidine dehydrogenase deficiency
- Authors:
- Maillard, Maud
Launay, Manon
Royer, Bernard
Guitton, Jérôme
Gautier‐Veyret, Elodie
Broutin, Sophie
Tron, Camille
Le Louedec, Félicien
Ciccolini, Joseph
Richard, Damien
Alarcan, Hugo
Haufroid, Vincent
Tafzi, Naïma
Schmitt, Antonin
Etienne‐Grimaldi, Marie‐Christine
Narjoz, Céline
Thomas, Fabienne - Other Names:
- Rieder Michael guestEditor.
Likic Robert guestEditor. - Abstract:
- Abstract : Aims: Determining dihydropyrimidine dehydrogenase (DPD) activity by measuring patient's uracil (U) plasma concentration is mandatory before fluoropyrimidine (FP) administration in France. In this study, we aimed to refine the pre‐analytical recommendations for determining U and dihydrouracil (UH2 ) concentrations, as they are essential in reliable DPD‐deficiency testing. Methods: U and UH2 concentrations were collected from 14 hospital laboratories. Stability in whole blood and plasma after centrifugation, the type of anticoagulant and long‐term plasma storage were evaluated. The variation induced by time and temperature was calculated and compared to an acceptability range of ±20%. Inter‐occasion variability (IOV) of U and UH2 was assessed in 573 patients double sampled for DPD‐deficiency testing. Results: Storage of blood samples before centrifugation at room temperature (RT) should not exceed 1 h, whereas cold (+4°C) storage maintains the stability of uracil after 5 hours. For patients correctly double sampled, IOV of U reached 22.4% for U (SD = 17.9%, range = 0–99%). Notably, 17% of them were assigned with a different phenotype (normal or DPD‐deficient) based on the analysis of their two samples. For those having at least one non‐compliant sample, this percentage increased up to 33.8%. The moment of blood collection did not affect the DPD phenotyping result. Conclusion: Caution should be taken when interpreting U concentrations if the time beforeAbstract : Aims: Determining dihydropyrimidine dehydrogenase (DPD) activity by measuring patient's uracil (U) plasma concentration is mandatory before fluoropyrimidine (FP) administration in France. In this study, we aimed to refine the pre‐analytical recommendations for determining U and dihydrouracil (UH2 ) concentrations, as they are essential in reliable DPD‐deficiency testing. Methods: U and UH2 concentrations were collected from 14 hospital laboratories. Stability in whole blood and plasma after centrifugation, the type of anticoagulant and long‐term plasma storage were evaluated. The variation induced by time and temperature was calculated and compared to an acceptability range of ±20%. Inter‐occasion variability (IOV) of U and UH2 was assessed in 573 patients double sampled for DPD‐deficiency testing. Results: Storage of blood samples before centrifugation at room temperature (RT) should not exceed 1 h, whereas cold (+4°C) storage maintains the stability of uracil after 5 hours. For patients correctly double sampled, IOV of U reached 22.4% for U (SD = 17.9%, range = 0–99%). Notably, 17% of them were assigned with a different phenotype (normal or DPD‐deficient) based on the analysis of their two samples. For those having at least one non‐compliant sample, this percentage increased up to 33.8%. The moment of blood collection did not affect the DPD phenotyping result. Conclusion: Caution should be taken when interpreting U concentrations if the time before centrifugation exceeds 1 hour at RT, since it rises significantly afterwards. Not respecting the pre‐analytical conditions for DPD phenotyping increases the risk of DPD status misclassification. Abstract : … (more)
- Is Part Of:
- British journal of clinical pharmacology. Volume 89:Issue 2(2023)
- Journal:
- British journal of clinical pharmacology
- Issue:
- Volume 89:Issue 2(2023)
- Issue Display:
- Volume 89, Issue 2 (2023)
- Year:
- 2023
- Volume:
- 89
- Issue:
- 2
- Issue Sort Value:
- 2023-0089-0002-0000
- Page Start:
- 762
- Page End:
- 772
- Publication Date:
- 2022-10-03
- Subjects:
- dihydrouracil -- dihydropyrimidine dehydrogenase -- intra‐individual variability -- pre‐analytical practices -- uracil
Pharmacology -- Periodicals
Drugs -- Periodicals
615.1 - Journal URLs:
- http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1365-2125 ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1111/bcp.15536 ↗
- Languages:
- English
- ISSNs:
- 0306-5251
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 2307.180000
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 25169.xml